What is InDevR?
InDevR specializes in the development of advanced analytical instrumentation designed to revolutionize vaccine development and serological research. By providing high-precision protein characterization tools, the company addresses the critical bottlenecks often encountered in biopharmaceutical production. Their product portfolio is engineered to enhance the efficiency and reliability of vaccine manufacturing, a sector that has seen heightened demand for rapid, scalable solutions. Beyond its hardware offerings, InDevR provides specialized testing and custom services, positioning itself as an essential partner for biotherapeutic companies navigating the complexities of regulatory compliance and quality control in the life sciences industry.
How much funding has InDevR raised?
InDevR has raised a total of $19.3M across 4 funding rounds:
Grant
$2.9M
Series A
$7M
Debt
$350K
Series B
$9M
Grant (2014): $2.9M with participation from National Institute of Allergy and Infectious Diseases
Series A (2019): $7M led by Adjuvant Capital
Debt (2020): $350K supported by PPP
Series B (2023): $9M featuring BioMérieux Turkey and Adjuvant Capital
Key Investors in InDevR
Adjuvant Capital
Adjuvant Capital is a venture capital firm focused on financing innovative life science technologies that address high-burden public health challenges. The firm prioritizes investments in infectious diseases and maternal health to drive both social impact and financial returns.
National Institute of Allergy and Infectious Diseases
A federal agency within the NIH that conducts and supports research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.
BioMérieux Turkey
A subsidiary of the global leader in in vitro diagnostics, focusing on clinical and industrial applications to improve patient health and consumer safety.
What's next for InDevR?
With the infusion of this latest capital, InDevR is well-positioned to scale its manufacturing capabilities and expand its footprint in the global bioprocessing market. The strategic focus will likely center on the commercialization of its next-generation analytical platforms, which are vital for the rapid deployment of vaccines against emerging infectious diseases. By leveraging its established partnerships with global health organizations and private investors, InDevR aims to solidify its role as a cornerstone of modern vaccine infrastructure. Future growth will likely involve deepening its service offerings for biotherapeutic developers, ensuring that its protein characterization technology remains at the forefront of the industry's push toward more agile and cost-effective manufacturing processes.
See full InDevR company page
